Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC

Background & Aims: Atezolizumab/bevacizumab (A/B) and durvalumab ± tremelimumab (DT/D) are preferred first-line regimens for the treatment of hepatocellular carcinoma (HCC). Although both therapies share an anti-PD-L1-backbone, only the A/B-combination is targeting vascular-endothelial-growth-fa...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Najib Ben Khaled, Raphael Mohr, Leonie S. Jochheim, Valentina Zarka, Monika Karin, Fabian Artusa, Julia M. Schütte, Vera Himmelsbach, Ursula Ehmer, Katrin Böttcher, Friedrich Foerster, Simon Johannes Gairing, Paula Bark, Alexander Weich, Ignazio Piseddu, Monika Rau, Bernhard Scheiner, Lorenz Balcar, Marino Venerito, Philipp Heumann, Arne Kandulski, Catherine Leyh, Christoph Roderburg, Tom Lüdde, Matthias Pinter, Julia Mayerle, Jens U. Marquardt, Fabian Finkelmeier, Enrico N. De Toni, Andreas Geier, Florian P. Reiter
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2026-06-01
Цуврал:	JHEP Reports
Нөхцлүүд:	Hepatocellular carcinoma Immunotherapy VEGF inhibitors Bleeding risk Thromboembolic events
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2589555926000893
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!